ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients

Belli, Luca S, Duvoux, Christophe, Berenguer, Marina, Berg, Thomas, Coilly, Audrey, Colle, Isabelle, Fagiuoli, Stefano, Khoo, Saye ORCID: 0000-0002-2769-0967, Pageaux, Georges Philippe, Puoti, Massimo
et al (show 2 more authors) (2017) ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. JOURNAL OF HEPATOLOGY, 67 (3). pp. 585-602.

[img] Text
PIIS016882781730140X.pdf - Author Accepted Manuscript

Download (816kB)


The advent of safe and highly effective direct-acting antiviral agents (DAAs) has had huge implications for the hepatitis C virus (HCV) transplant field, and changed our management of both patients on the waiting list and those with HCV graft re-infection after liver transplantation (LT). When treating HCV infection before LT, HCV re-infection of the graft can be prevented in nearly all patients. In addition, some candidates show a remarkable clinical improvement and may be delisted. Alternatively, HCV infection can be treated post-LT either soon after the transplant, taking advantage of the removal of the infected native liver, or at the time of disease recurrence, as was carried out in the past. In either case, some DAAs have a limited use because of their drug to drug interactions with various immunosuppressants as well as the many other drugs liver transplant recipients are often prescribed. In addition, some DAAs should be avoided in case of severe renal failure, which is not an unusual complication after LT. The present document provides a series of consensus statements on the LT issues that have not been extensively addressed previously. These statements have been developed to support physicians and other stakeholders in charge of LT candidates and recipients when deciding to treat HCV, especially in difficult situations.

Item Type: Article
Uncontrolled Keywords: Antiviral agents, Liver transplantation, Liver transplant candidate, Liver transplant recipient, Recurrent hepatitis C, Hepatitis C, chronic, Interferons, Guidelines, Waiting lists, Liver failure
Depositing User: Symplectic Admin
Date Deposited: 17 May 2017 06:36
Last Modified: 19 Jan 2023 07:05
DOI: 10.1016/j.jhep.2017.03.006
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3007124